OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...

B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...

Researchers have identified organized clusters of B cells in the kidneys of some diabetic kidney disease patients, linked to faster progression toward kidney failure. Using advanced spatial mapping of ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...

Our immune systems have the thankless jobs of guarding us from bacterial and viral invaders and preventing cancer development. Most of the time, we do not notice this hard work because the invaders ...

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...